What is Haemonetics's EV / EBITDA?

Haemonetics (HAE) reported EV / EBITDA of 12.7× in Q4 2025.

How has Haemonetics's EV / EBITDA changed year-over-year?

Haemonetics's EV / EBITDA decreased by 22.3% year-over-year, from 16.3× to 12.7×.

What is the long-term trend for Haemonetics's EV / EBITDA?

Over 4 years (2021 to 2025), Haemonetics's EV / EBITDA has grown at a -23.4% compound annual growth rate (CAGR), from 36× to 12.4×.

What does EV / EBITDA mean?

Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Haemonetics HAE EV / EBITDA

EV / EBITDA at other companies

AbbottABT

18.9×-4.1×

TFX

TeleflexTFX

26.8×+7.6×

Boston ScientificBSX

28.3×-8.5×

MedtronicMDT

13.9×-1.5×

LivaNovaLIVN

13.6×+3.1×

ICU MedicalICUI

17.4×+0.4×

Other financials

Income statement

See full

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

See full

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

See full

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

See full

Market cap$3.37B-18.0%

Enterprise value$4.4B-12.5%

P/S2.5×-0.5×

Profitability

See full

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Calculated from Haemonetics’s reported figures.

enterprise value/ebitda=12.7×

Based on the most recent quarter.

The official record: Haemonetics’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Haemonetics's EV / EBITDA?: Haemonetics (HAE) reported EV / EBITDA of 12.7× in Q4 2025.
How has Haemonetics's EV / EBITDA changed year-over-year?: Haemonetics's EV / EBITDA decreased by 22.3% year-over-year, from 16.3× to 12.7×.
What is the long-term trend for Haemonetics's EV / EBITDA?: Over 4 years (2021 to 2025), Haemonetics's EV / EBITDA has grown at a -23.4% compound annual growth rate (CAGR), from 36× to 12.4×.
What does EV / EBITDA mean?: Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.